Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2012
Search for a gene expression signature of breast cancer local recurrence in young womenNicolas Servant, Marc A Bollet, Hans Halfwerk, et al.
Plos One|June 10, 2011
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinomaFabien Reyal, Roman Rouzier, Berenice Depont-Hazelzet, et al.
Plos One|November 17, 2011
External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvementDavid Hajage, Yann de Rycke, Marc Bollet, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2009
Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinomaAnne Vincent-Salomon, Martial Caly, Yann De Rycke, et al.
Plos One|February 28, 2017
Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancersHélène Bonsang-Kitzis, Delphine Mouttet-Boizat, Eugénie Guillot, et al.
Cancer Research|August 31, 2012
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivationTatiana Popova, Elodie Manié, Guillaume Rieunier, et al.
Familial Cancer|June 20, 2012
Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcomePascale This, Anne de la Rochefordière, Alexia Savignoni, et al.
International Journal of Cancer|August 29, 2015
Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomasElodie Manié, Tatiana Popova, Aude Battistella, et al.
Plos One|October 2, 2009
8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosisSylvie Rodrigues-Ferreira, Anne Di Tommaso, Ariane Dimitrov, et al.
BMC Cancer|June 3, 2011
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPatricia de Cremoux, Fabien Valet, David Gentien, et al.
Pageof 8